1
|
Droppa-Almeida D, Vivas WLP, Silva KKO, Rezende AFS, Simionatto S, Meyer R, Lima-Verde IB, Delagostin O, Borsuk S, Padilha FF. Recombinant CP40 from Corynebacterium pseudotuberculosis confers protection in mice after challenge with a virulent strain. Vaccine 2016; 34:1091-6. [PMID: 26796140 DOI: 10.1016/j.vaccine.2015.12.064] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2015] [Revised: 12/28/2015] [Accepted: 12/29/2015] [Indexed: 01/30/2023]
Abstract
BACKGROUND Caseous Lymphadenitis (CLA) is a contagious, infectious, chronic disease caused by Corynebacterium pseudotuberculosis, which affects mainly sheep and goats. The clinical prevalence of CLA in Brazil is 30%, resulting in decreased milk production, weight loss, and unusable meat and leather. Prophylaxis is based on vaccination; however, current vaccinations do not offer effective protection against the infection, which makes the development of a new vaccine essential to control this disease. EXPERIMENTAL APPROACH Here, we developed a recombinant vaccine based on CP40 protein (rCP40) combined with an adjuvant (Freund's complete adjuvant or saponin) and evaluated its efficacy in a murine model of CLA. Female BALB/c mice were used in an immunization assay. KEY RESULTS rCP40 induced high levels of IgG2a and IgG2b antibodies. After challenge with a virulent strain of C. pseudotuberculosis C57 (10(4)CFU/mL), the levels of IgG2a and IgG2b were sustained, indicating a Th1 response. The groups immunized with rCP40 protein (GES and GEF groups) showed 100% protection and was statistically significant in the GES and GEF groups (p<0.037 and p<0.0952, respectively). CONCLUSIONS The results indicated the recombinant protein CP40 induced an specific immune response in mice that was able to afford protection after challenge, regardless the adjuvant used in the formulation.
Collapse
Affiliation(s)
- Daniela Droppa-Almeida
- Instituto de Tecnologia e Pesquisa - Universidade Tiradentes, Avenida Murilo Dantas, 300, Farolândia, Aracaju, Sergipe 49032-490, Brazil
| | - Wanessa L P Vivas
- Instituto de Tecnologia e Pesquisa - Universidade Tiradentes, Avenida Murilo Dantas, 300, Farolândia, Aracaju, Sergipe 49032-490, Brazil
| | - Katharina Kelly O Silva
- Instituto de Tecnologia e Pesquisa - Universidade Tiradentes, Avenida Murilo Dantas, 300, Farolândia, Aracaju, Sergipe 49032-490, Brazil
| | - Andrea F S Rezende
- Centro de Biotecnologia - Universidade Federal de Pelotas, Campus Capão do Leão, Capão do Leão, Rio Grande do Sul 96010-900, Brazil
| | - Simone Simionatto
- Faculdade de Ciências Biológicas e Ambientais - Universidade Federal da Grande Dourados, Rodovia Dourados - Itahum, Km 12 - Cidade Universitária, Mato Grosso do Sul 79804-970, Brazil
| | - Roberto Meyer
- Instituto de Ciências da Saúde - Universidade Federal da Bahia Avenida Reitor Miguel Calmon s/n, Vale do Canela, Salvador, BA 40110-100, Brazil
| | - Isabel B Lima-Verde
- Instituto de Tecnologia e Pesquisa - Universidade Tiradentes, Avenida Murilo Dantas, 300, Farolândia, Aracaju, Sergipe 49032-490, Brazil
| | - Odir Delagostin
- Centro de Biotecnologia - Universidade Federal de Pelotas, Campus Capão do Leão, Capão do Leão, Rio Grande do Sul 96010-900, Brazil
| | - Sibele Borsuk
- Centro de Biotecnologia - Universidade Federal de Pelotas, Campus Capão do Leão, Capão do Leão, Rio Grande do Sul 96010-900, Brazil.
| | - Francine F Padilha
- Instituto de Tecnologia e Pesquisa - Universidade Tiradentes, Avenida Murilo Dantas, 300, Farolândia, Aracaju, Sergipe 49032-490, Brazil.
| |
Collapse
|
2
|
Giles C, Vanniasinkam T, Ndi S, Barton MD. Rhodococcus equi (Prescottella equi)vaccines; the future of vaccine development. Equine Vet J 2014; 47:510-8. [DOI: 10.1111/evj.12310] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2014] [Accepted: 06/12/2014] [Indexed: 12/29/2022]
Affiliation(s)
- C. Giles
- School of Pharmacy and Medical Sciences; University of South Australia; Adelaide Australia
| | - T. Vanniasinkam
- School of Biomedical Sciences; Charles Sturt University; Wagga Wagga New South Wales Australia
| | - S. Ndi
- School of Pharmacy and Medical Sciences; University of South Australia; Adelaide Australia
| | - M. D. Barton
- School of Pharmacy and Medical Sciences; University of South Australia; Adelaide Australia
| |
Collapse
|
3
|
Lu Z, Rynkiewicz MJ, Madico G, Li S, Yang CY, Perkins HM, Sompuram SR, Kodela V, Liu T, Morris T, Wang D, Roche MI, Seaton BA, Sharon J. B-cell epitopes in GroEL of Francisella tularensis. PLoS One 2014; 9:e99847. [PMID: 24968190 PMCID: PMC4072690 DOI: 10.1371/journal.pone.0099847] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Accepted: 05/16/2014] [Indexed: 01/01/2023] Open
Abstract
The chaperonin protein GroEL, also known as heat shock protein 60 (Hsp60), is a prominent antigen in the human and mouse antibody response to the facultative intracellular bacterium Francisella tularensis (Ft), the causative agent of tularemia. In addition to its presumed cytoplasmic location, FtGroEL has been reported to be a potential component of the bacterial surface and to be released from the bacteria. In the current study, 13 IgG2a and one IgG3 mouse monoclonal antibodies (mAbs) specific for FtGroEL were classified into eleven unique groups based on shared VH-VL germline genes, and seven crossblocking profiles revealing at least three non-overlapping epitope areas in competition ELISA. In a mouse model of respiratory tularemia with the highly pathogenic Ft type A strain SchuS4, the Ab64 and N200 IgG2a mAbs, which block each other’s binding to and are sensitive to the same two point mutations in FtGroEL, reduced bacterial burden indicating that they target protective GroEL B-cell epitopes. The Ab64 and N200 epitopes, as well as those of three other mAbs with different crossblocking profiles, Ab53, N3, and N30, were mapped by hydrogen/deuterium exchange–mass spectrometry (DXMS) and visualized on a homology model of FtGroEL. This model was further supported by its experimentally-validated computational docking to the X-ray crystal structures of Ab64 and Ab53 Fabs. The structural analysis and DXMS profiles of the Ab64 and N200 mAbs suggest that their protective effects may be due to induction or stabilization of a conformational change in FtGroEL.
Collapse
Affiliation(s)
- Zhaohua Lu
- Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Michael J. Rynkiewicz
- Department of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Guillermo Madico
- Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
- Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Sheng Li
- Department of Medicine, University of California, San Diego, School of Medicine, San Diego, California, United States of America
| | - Chiou-Ying Yang
- Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
- Institute of Molecular Biology, National Chung Hsing University, Taichung, Taiwan
| | - Hillary M. Perkins
- Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Seshi R. Sompuram
- Medical Discovery Partners, LLC, Boston, Massachusetts, United States of America
| | - Vani Kodela
- Medical Discovery Partners, LLC, Boston, Massachusetts, United States of America
| | - Tong Liu
- Department of Medicine, University of California, San Diego, School of Medicine, San Diego, California, United States of America
| | - Timothy Morris
- Department of Medicine, University of California, San Diego, School of Medicine, San Diego, California, United States of America
| | - Daphne Wang
- Department of Medicine, University of California, San Diego, School of Medicine, San Diego, California, United States of America
| | - Marly I. Roche
- Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Barbara A. Seaton
- Department of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Jacqueline Sharon
- Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
- * E-mail:
| |
Collapse
|
4
|
Costa MP, McCulloch JA, Almeida SS, Dorella FA, Fonseca CT, Oliveira DM, Teixeira MF, Laskowska E, Lipinska B, Meyer R, Portela RW, Oliveira SC, Miyoshi A, Azevedo V. Molecular characterization of the Corynebacterium pseudotuberculosis hsp60-hsp10 operon, and evaluation of the immune response and protective efficacy induced by hsp60 DNA vaccination in mice. BMC Res Notes 2011; 4:243. [PMID: 21774825 PMCID: PMC3158118 DOI: 10.1186/1756-0500-4-243] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2011] [Accepted: 07/20/2011] [Indexed: 01/12/2023] Open
Abstract
Background Heat shock proteins (HSPs) are important candidates for the development of vaccines because they are usually able to promote both humoral and cellular immune responses in mammals. We identified and characterized the hsp60-hsp10 bicistronic operon of the animal pathogen Corynebacterium pseudotuberculosis, a Gram-positive bacterium of the class Actinobacteria, which causes caseous lymphadenitis (CLA) in small ruminants. Findings To construct the DNA vaccine, the hsp60 gene of C. pseudotuberculosis was cloned in a mammalian expression vector. BALB/c mice were immunized by intramuscular injection with the recombinant plasmid (pVAX1/hsp60). Conclusion This vaccination induced significant anti-hsp60 IgG, IgG1 and IgG2a isotype production. However, immunization with this DNA vaccine did not confer protective immunity.
Collapse
Affiliation(s)
- Marcilia P Costa
- Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av, Antonio Carlos, 6627 - Pampulha, CP 486, CEP 31,270-901, Belo Horizonte- MG, Brazil.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Dawson TRMY, Horohov DW, Meijer WG, Muscatello G. Current understanding of the equine immune response to Rhodococcus equi. An immunological review of R. equi pneumonia. Vet Immunol Immunopathol 2009; 135:1-11. [PMID: 20064668 DOI: 10.1016/j.vetimm.2009.12.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2009] [Revised: 12/11/2009] [Accepted: 12/16/2009] [Indexed: 10/20/2022]
Abstract
Rhodococcus equi is recognised to cause chronic purulent bronchopneumonia in foals of less than 6 months of age. Virulent strains of the bacteria possess a large 80-90 kb plasmid encoding several virulence-associated proteins, including virulence-associated protein A (VapA), which is associated with disease. R. equi pneumonia can represent significant costs and wastage to the equine breeding industry, especially on stud farms where the disease is endemic. This article reviews knowledge of the equine immune response, both in the immune adult and susceptible neonate, with respect to this pathogen. Humoral immune responses are addressed, with a discussion on the use of hyperimmune and normal adult equine plasma as prophylactic tools. The role that innate immune mechanisms play in the susceptibility of some foals to R. equi infection is also highlighted. Likewise, cell-mediated immune components are reviewed, with particular attention directed towards research undertaken to develop an effective vaccine for foals. It is possible that the implementation of a single immunoprophylaxis strategy to prevent R. equi infection on farms will yield disappointing results. Combined prophylactic protocols that address husbandry practices, environmental and aerosol contamination levels, enhancement of innate immunity, good quality hyperimmune plasma for the neonate, and vaccinal efficacy in the developing foal may be required.
Collapse
Affiliation(s)
- Tamsin R M Y Dawson
- The Faculty of Applied Sciences, University of Sunderland, Fleming Building, Wharncliffe Street, Sunderland SR1 3SD, UK.
| | - David W Horohov
- Department of Veterinary Science, University of Kentucky, UK
| | - Wim G Meijer
- School of Biomolecular and Biomedical Science, University College Dublin, Ireland
| | - Gary Muscatello
- Faculty of Veterinary Science, The University of Sydney, Australia
| |
Collapse
|
6
|
Barbey C, Budin-Verneuil A, Cauchard S, Hartke A, Laugier C, Pichereau V, Petry S. Proteomic analysis and immunogenicity of secreted proteins from Rhodococcus equi ATCC 33701. Vet Microbiol 2008; 135:334-45. [PMID: 19019579 DOI: 10.1016/j.vetmic.2008.09.086] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2008] [Revised: 09/19/2008] [Accepted: 09/24/2008] [Indexed: 10/21/2022]
Abstract
Rhodococcus equi is one of the most important causes of mortality in foals between 1 and 6 months of age. Although rare, infection also occurs in a variety of other mammals including humans, often following immunosuppression of various causes. Secreted proteins are known to mediate important pathogen-host interactions and consequently are favored candidates for vaccine development as they are the most easily accessible microbial antigens to the immune system. Here, we describe the results of a proteomic analysis based on SDS-PAGE, immunoblot and mass spectrometry, which was carried out aiming the identification of secreted proteins that are differently expressed at 30 degrees C versus 37 degrees C and at mid-exponential versus early-stationary growth phase and antigenic proteins from R. equi ATCC 33701. A total of 48 proteins was identified regardless of growth conditions. The cholesterol oxidase ChoE appears to be the major secretory protein. Moreover, four proteins revealed high homologies with the mycolyl transferases of the Ag85 complex from Mycobacterium tuberculosis. The sequence analysis predicted that 24 proteins are transported by a signal peptide-dependent pathway. Moreover, five antigenic proteins of R. equi were identified by immunoblot, including a novel strongly immunoreactive protein of unknown function. In conclusion, the elucidation of the secretome of R. equi identified several proteins with different biological functions and a new candidate for developing vaccines against R. equi infection in horse.
Collapse
Affiliation(s)
- Corinne Barbey
- AFSSA, Laboratoire d'Etudes et de Recherches en Pathologie Equine, IPC, Goustranville, 14430 Dozulé, France
| | | | | | | | | | | | | |
Collapse
|
7
|
Phumoonna T, Barton MD, Vanniasinkam T, Heuzenroeder MW. Chimeric vapA/groEL2 DNA vaccines enhance clearance of Rhodococcus equi in aerosol challenged C3H/He mice. Vaccine 2008; 26:2457-65. [DOI: 10.1016/j.vaccine.2008.03.015] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2007] [Revised: 01/31/2008] [Accepted: 03/12/2008] [Indexed: 10/22/2022]
|
8
|
Crampton A, Vanniasinkam T. Parasite vaccines: The new generation. INFECTION GENETICS AND EVOLUTION 2007; 7:664-73. [PMID: 17702669 DOI: 10.1016/j.meegid.2007.06.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/23/2006] [Revised: 06/25/2007] [Accepted: 06/27/2007] [Indexed: 12/24/2022]
Abstract
Parasites cause some of the most devastating and prevalent diseases in humans and animals. Moreover, parasitic infections increase mortality rates of other serious non-parasitic infections caused by pathogens such as HIV-1. The impact of parasitic diseases in both industrialised and developing countries is further exacerbated by the resistance of some parasites to anti-parasitic drugs and the absence of efficacious parasite vaccines. Despite years of research, much remains to be done to develop effective vaccines against parasites. This review focuses on the more recent vaccine strategies such as DNA and viral vector-based vaccines that are currently being used to develop vaccines against parasites. Obstacles yet to be overcome and possible advantages and disadvantages of these vaccine modalities are also discussed.
Collapse
Affiliation(s)
- A Crampton
- School of Biomedical Sciences, Charles Sturt University, Locked Bag 678, Wagga Wagga, NSW 2650, Australia
| | | |
Collapse
|
9
|
Vanniasinkam T, Barton MD, Heuzenroeder MW. Immune response to vaccines based upon the VapA protein of the horse pathogen, Rhodococcus equi, in a murine model. Int J Med Microbiol 2005; 294:437-45. [PMID: 15715172 DOI: 10.1016/j.ijmm.2004.09.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
Rhodococcus equi is a significant pathogen in foals predominantly causing a pyogranulomatous bronchopneumonia. Many vaccine candidates have been tested for the prevention of R. equi disease in foals. However, none of these have been developed for widespread commercial use. Previous studies have shown that a Th1 immune response is imperative for the protection of foals against R. equi disease. In this study a DNA and a protein vaccine based upon the well-characterised R. equi virulence-associated protein VapA were developed. The vaccines were tested in the BALB/c murine model and the results showed that both vaccine candidates elicited a Th1-type response in the host. Upon coadministration of an IL-12 expression plasmid with the DNA vaccine, an increase in the Th1 response was observed. However, when mice were challenged with 1.5 x 10(7) virulent R. equi ATCC 33701 none of the vaccinated mice showed protection apart from the mice immunised with live R. equi. These results indicate that despite their immunogenicity the VapA-based DNA and recombinant protein vaccines developed in this study were unable to prevent bacterial replication following a high-dose systemic challenge with virulent R. equi in the BALB/c model.
Collapse
Affiliation(s)
- Thiru Vanniasinkam
- Infectious Diseases Laboratories, Institute of Medical and Veterinary Science, P.O. Box 14, Rundle Mall, Adelaide, SA 5000, Australia
| | | | | |
Collapse
|